Baidu
map

EUR J Cancer:成人实体肿瘤患者化疗治疗期间流感疫苗的接种

2017-12-28 MedSci MedSci原创

接受化疗的实体瘤患者广泛面临着流感并发症的风险,因此医生建议接受化疗的患者每年都要接种流感疫苗。然而,流感疫苗在化疗期间接种的有效性,最佳接种时机和安全性都缺乏实际证据。 目前也尚无流感疫苗是否能在成人实体瘤化疗期间减少肺炎、降低死亡率和减少肿瘤治疗的中断的直接证据。

接受化疗的实体瘤患者广泛面临着流感并发症的风险,因此医生建议接受化疗的患者每年都要接种流感疫苗。然而,流感疫苗在化疗期间接种的有效性,最佳接种时机和安全性都缺乏实际证据。 目前也尚无流感疫苗是否能在成人实体瘤化疗期间减少肺炎、降低死亡率和减少肿瘤治疗的中断的直接证据。

研究人员综合了20个非随机的不同癌症成年患者的血清学临床研究,总体而言,化疗组流感疫苗接种后的抗体反应的程度低于健康对照组。但不管化疗进度如何,大部分实体瘤患者能够及时产生保护性免疫反应(即血清保护),该数据与健康对照相似。结果显示,灭活的流感疫苗对免疫抑制患者是安全的,且副作用与健康对照组相似。尽管在开始化疗前接种疫苗能够确保实体瘤成人患者获得最佳保护,但化疗期间接种疫苗同样可以减少流感相关并发症的发生。

因此,鉴于流行性感冒的发病率和死亡率,医生应该提倡廉价而安全的流感疫苗的接种来预防接受化疗患者的流感并发症。 

原始出处:

Vollaard, Albert, et al. "Influenza vaccination in adult patients with solid tumours treated with chemotherapy." European Journal of Cancer 2017 76: 134-143. doi.org/10.1016/j.ejca.

本文系梅斯医学(MedSci)原创编译整理,转载需授权

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1798815, encodeId=0a0b1e98815ed, content=<a href='/topic/show?id=d342e0516bd' target=_blank style='color:#2F92EE;'>#疫苗的接种#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70516, encryptionId=d342e0516bd, topicName=疫苗的接种)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8ca5383, createdName=bbjsj_1979, createdTime=Fri Feb 16 17:32:00 CST 2018, time=2018-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=276580, encodeId=a4ac2e6580ab, content=学习并分享!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200816/e4675a86ea694f12b82202b320dc2654/12f6b900498349e994ce8f516a584d6a.jpg, createdBy=09431951290, createdName=大爰, createdTime=Mon Jan 08 09:52:54 CST 2018, time=2018-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1379149, encodeId=8cb913e9149c9, content=<a href='/topic/show?id=49ed460213b' target=_blank style='color:#2F92EE;'>#实体肿瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46021, encryptionId=49ed460213b, topicName=实体肿瘤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1c77441, createdName=weiz, createdTime=Sat Dec 30 08:32:00 CST 2017, time=2017-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1424224, encodeId=63401424224d8, content=<a href='/topic/show?id=94c182929d0' target=_blank style='color:#2F92EE;'>#肿瘤患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82929, encryptionId=94c182929d0, topicName=肿瘤患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=60943920553, createdName=lanyan20020087, createdTime=Sat Dec 30 08:32:00 CST 2017, time=2017-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=273536, encodeId=c1752e3536b2, content=学习了谢谢分享!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200816/e4675a86ea694f12b82202b320dc2654/12f6b900498349e994ce8f516a584d6a.jpg, createdBy=09431951290, createdName=大爰, createdTime=Fri Dec 29 16:05:12 CST 2017, time=2017-12-29, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1798815, encodeId=0a0b1e98815ed, content=<a href='/topic/show?id=d342e0516bd' target=_blank style='color:#2F92EE;'>#疫苗的接种#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70516, encryptionId=d342e0516bd, topicName=疫苗的接种)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8ca5383, createdName=bbjsj_1979, createdTime=Fri Feb 16 17:32:00 CST 2018, time=2018-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=276580, encodeId=a4ac2e6580ab, content=学习并分享!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200816/e4675a86ea694f12b82202b320dc2654/12f6b900498349e994ce8f516a584d6a.jpg, createdBy=09431951290, createdName=大爰, createdTime=Mon Jan 08 09:52:54 CST 2018, time=2018-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1379149, encodeId=8cb913e9149c9, content=<a href='/topic/show?id=49ed460213b' target=_blank style='color:#2F92EE;'>#实体肿瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46021, encryptionId=49ed460213b, topicName=实体肿瘤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1c77441, createdName=weiz, createdTime=Sat Dec 30 08:32:00 CST 2017, time=2017-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1424224, encodeId=63401424224d8, content=<a href='/topic/show?id=94c182929d0' target=_blank style='color:#2F92EE;'>#肿瘤患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82929, encryptionId=94c182929d0, topicName=肿瘤患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=60943920553, createdName=lanyan20020087, createdTime=Sat Dec 30 08:32:00 CST 2017, time=2017-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=273536, encodeId=c1752e3536b2, content=学习了谢谢分享!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200816/e4675a86ea694f12b82202b320dc2654/12f6b900498349e994ce8f516a584d6a.jpg, createdBy=09431951290, createdName=大爰, createdTime=Fri Dec 29 16:05:12 CST 2017, time=2017-12-29, status=1, ipAttribution=)]
    2018-01-08 大爰

    学习并分享!!

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1798815, encodeId=0a0b1e98815ed, content=<a href='/topic/show?id=d342e0516bd' target=_blank style='color:#2F92EE;'>#疫苗的接种#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70516, encryptionId=d342e0516bd, topicName=疫苗的接种)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8ca5383, createdName=bbjsj_1979, createdTime=Fri Feb 16 17:32:00 CST 2018, time=2018-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=276580, encodeId=a4ac2e6580ab, content=学习并分享!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200816/e4675a86ea694f12b82202b320dc2654/12f6b900498349e994ce8f516a584d6a.jpg, createdBy=09431951290, createdName=大爰, createdTime=Mon Jan 08 09:52:54 CST 2018, time=2018-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1379149, encodeId=8cb913e9149c9, content=<a href='/topic/show?id=49ed460213b' target=_blank style='color:#2F92EE;'>#实体肿瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46021, encryptionId=49ed460213b, topicName=实体肿瘤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1c77441, createdName=weiz, createdTime=Sat Dec 30 08:32:00 CST 2017, time=2017-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1424224, encodeId=63401424224d8, content=<a href='/topic/show?id=94c182929d0' target=_blank style='color:#2F92EE;'>#肿瘤患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82929, encryptionId=94c182929d0, topicName=肿瘤患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=60943920553, createdName=lanyan20020087, createdTime=Sat Dec 30 08:32:00 CST 2017, time=2017-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=273536, encodeId=c1752e3536b2, content=学习了谢谢分享!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200816/e4675a86ea694f12b82202b320dc2654/12f6b900498349e994ce8f516a584d6a.jpg, createdBy=09431951290, createdName=大爰, createdTime=Fri Dec 29 16:05:12 CST 2017, time=2017-12-29, status=1, ipAttribution=)]
    2017-12-30 weiz
  4. [GetPortalCommentsPageByObjectIdResponse(id=1798815, encodeId=0a0b1e98815ed, content=<a href='/topic/show?id=d342e0516bd' target=_blank style='color:#2F92EE;'>#疫苗的接种#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70516, encryptionId=d342e0516bd, topicName=疫苗的接种)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8ca5383, createdName=bbjsj_1979, createdTime=Fri Feb 16 17:32:00 CST 2018, time=2018-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=276580, encodeId=a4ac2e6580ab, content=学习并分享!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200816/e4675a86ea694f12b82202b320dc2654/12f6b900498349e994ce8f516a584d6a.jpg, createdBy=09431951290, createdName=大爰, createdTime=Mon Jan 08 09:52:54 CST 2018, time=2018-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1379149, encodeId=8cb913e9149c9, content=<a href='/topic/show?id=49ed460213b' target=_blank style='color:#2F92EE;'>#实体肿瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46021, encryptionId=49ed460213b, topicName=实体肿瘤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1c77441, createdName=weiz, createdTime=Sat Dec 30 08:32:00 CST 2017, time=2017-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1424224, encodeId=63401424224d8, content=<a href='/topic/show?id=94c182929d0' target=_blank style='color:#2F92EE;'>#肿瘤患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82929, encryptionId=94c182929d0, topicName=肿瘤患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=60943920553, createdName=lanyan20020087, createdTime=Sat Dec 30 08:32:00 CST 2017, time=2017-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=273536, encodeId=c1752e3536b2, content=学习了谢谢分享!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200816/e4675a86ea694f12b82202b320dc2654/12f6b900498349e994ce8f516a584d6a.jpg, createdBy=09431951290, createdName=大爰, createdTime=Fri Dec 29 16:05:12 CST 2017, time=2017-12-29, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1798815, encodeId=0a0b1e98815ed, content=<a href='/topic/show?id=d342e0516bd' target=_blank style='color:#2F92EE;'>#疫苗的接种#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70516, encryptionId=d342e0516bd, topicName=疫苗的接种)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8ca5383, createdName=bbjsj_1979, createdTime=Fri Feb 16 17:32:00 CST 2018, time=2018-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=276580, encodeId=a4ac2e6580ab, content=学习并分享!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200816/e4675a86ea694f12b82202b320dc2654/12f6b900498349e994ce8f516a584d6a.jpg, createdBy=09431951290, createdName=大爰, createdTime=Mon Jan 08 09:52:54 CST 2018, time=2018-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1379149, encodeId=8cb913e9149c9, content=<a href='/topic/show?id=49ed460213b' target=_blank style='color:#2F92EE;'>#实体肿瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46021, encryptionId=49ed460213b, topicName=实体肿瘤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1c77441, createdName=weiz, createdTime=Sat Dec 30 08:32:00 CST 2017, time=2017-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1424224, encodeId=63401424224d8, content=<a href='/topic/show?id=94c182929d0' target=_blank style='color:#2F92EE;'>#肿瘤患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82929, encryptionId=94c182929d0, topicName=肿瘤患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=60943920553, createdName=lanyan20020087, createdTime=Sat Dec 30 08:32:00 CST 2017, time=2017-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=273536, encodeId=c1752e3536b2, content=学习了谢谢分享!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200816/e4675a86ea694f12b82202b320dc2654/12f6b900498349e994ce8f516a584d6a.jpg, createdBy=09431951290, createdName=大爰, createdTime=Fri Dec 29 16:05:12 CST 2017, time=2017-12-29, status=1, ipAttribution=)]
    2017-12-29 大爰

    学习了谢谢分享!!

    0

相关资讯

PLoS Pathog:流感疫苗生产的方式导致流感病毒突变

根据美国斯克利普斯研究所(TSRI)的一项新研究,在鸡蛋中培养流感疫苗成分这种常见的方法扰乱了病毒表面主要抗体靶位点,使得流感疫苗对人类的效果减弱。

2017-18 ACIP建议:流感季节流感疫苗防控

2017年11月,美国免疫实践咨询委员会(ACIP)发布了流感季节流感疫苗防控建议。本文是对2016-17版流感疫苗防控建议的更新,针对特殊人群应用不同疫苗的建议进行讨论,并针对季节性流感疫苗以及疫苗接种等提供指导建议。

Sci Rep: “四合一”流感疫苗或能终身免疫?

根据内布拉斯加病毒学研究中心发表的一项新研究,一种疫苗结合了来自四种主要流感毒株集中的祖先基因,它能够针对危险的疾病提供广泛的保护作用。

流感疫苗对鸡蛋过敏者是安全的

随着美国进入一个潜在的流感季节,健康专家们提出了新的疫苗接种指南,告诉那些对鸡蛋过敏的人和那些没有过敏的人注射流感疫苗没有安全上的区别。从历史上看,卫生保健从业人员询问前流感疫苗接种者是否对鸡蛋过敏,有时在注射疫苗后对其进行监测。发表在《过敏、哮喘和免疫学年鉴》上的新指南说,医生甚至不需要询问接受者是否过敏。据专家介绍,以前担心疫苗中微量的蛋白可能引发过敏反应是没有根据的。美国大约2%的儿童对鸡蛋

流感疫苗,糖友和家人一起打

入秋后气温转冷,是流感的高发季。普通人得了流感,可能扛一扛就过去了。但糖友若是得了流感,症状会比常人更严重。因此,糖友必须特别重视预防流感,最有效的方式就是打疫苗。

Sci Rep:“四合一”流感疫苗或能终身免疫

根据内布拉斯加病毒学研究中心发表的一项新研究,一种疫苗结合了来自四种主要流感毒株集中的祖先基因,它能够针对危险的疾病提供广泛的保护作用。

Baidu
map
Baidu
map
Baidu
map